Figure 8.

Transcriptome high-throughput sequencing was used to study the effect of the 2Mg@PEG-PLGA gel on osteoporotic bone defect repair. (A) Schematic diagram of the RNA sequence analysis of extracted tissues within femoral bone defects from the control and 2Mg@PEG-PLGA groups at 4 weeks. (B) Volcano plot of genes that were differentially expressed between the control and 2Mg@PEG-PLGA groups. (C) Representative KEGG pathways associated with genes that were significantly differentially expressed between the control and 2Mg@PEG-PLGA groups. (D) Differentially expressed genes involved in the TNF-α signaling pathway. (E) IF images of TNF-α protein expression in femoral bone defects at 4 weeks. The white dotted lines mark the bone defects. Red fluorescence: TNF-α; blue fluorescence: DAPI. (F) Schematic illustration of the mechanism by which 2Mg@PEG-PLGA downregulates osteoclastogenesis and inflammation by inhibiting the TNF-α signaling pathway.